Skip to main content
Bildspel: 

Moberg Pharma’s Interim report for July 2019 - March 2020 to be published on May 12 - Invitation to teleconference

STOCKHOLM, May 5th, 2020 - On May 12th, 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - March 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.

The teleconference will be hosted by Moberg Pharmas’s CEO Anna Ljung and VP Finance Mark Beveridge. The presentation will be held in English.

Date:             May 12th, 2020
Time:             3:00 pm (CET)

To participate in the conference, please dial in on any number below before the start of the call:

SE:                     +46 8 505 583 69
US:                     +1 833 249 84 04

The quarterly report and other information material will be made public on:
http://www.mobergpharma.com/investors/calendarpresentations

For additional information, please contact:
Anna Ljung, CEO, Phone: + 46 70 766 60 30, e-post: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-post: mark.beveridge@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, with ongoing phase 3 studies covering more than 800 patients. Topline results from the North American study are now available, followed by results from the European study expected by the end of the quarter of 2020. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on Nasdaq Stockholm (OMX: MOB).